Screening for early colorectal cancer.

Area of Science:

• Oncology
• Preventive Medicine
• Gastroenterology

Background:

• Randomized trials demonstrate fecal occult blood tests (FOBTs) can decrease colorectal cancer mortality by 15-25%.
• Screening benefits are primarily linked to early cancer detection in average-risk individuals over 50, confirmed by colonoscopy.
• Widespread population acceptance and organizational infrastructure are crucial for successful national screening programs.

Purpose of the Study:

• To evaluate the effectiveness of FOBT screening in reducing colorectal cancer mortality.
• To assess the cost-effectiveness of colorectal cancer screening compared to other cancer screening methods.
• To review current guidelines and challenges in screening high-risk populations and families with hereditary colorectal cancer.

Main Methods:

• Review of randomized controlled trials on FOBT screening for colorectal cancer.
• Analysis of cost-effectiveness data for various cancer screening modalities.
• Examination of guidelines for screening average-risk and high-risk individuals, including those with a family history of colorectal neoplasia.

Main Results:

• FOBT screening shows potential for significant mortality reduction, particularly when positive tests lead to colonoscopy.
• Population-based studies have not yet consistently shown reduced incidence despite increased precursor removal.
• Cost-effectiveness is projected to be favorable, comparable to mammography and superior to cervical cancer screening.

Conclusions:

• FOBT screening is a viable strategy for reducing colorectal cancer mortality in average-risk populations.
• Further research is needed to optimize screening protocols, evaluate newer, more sensitive tests, and address high-risk group screening.
• Established guidelines exist for hereditary colorectal cancer syndromes, but consensus is lacking for other high-risk categories.